C-QUEST: Cuts Put Chemo Drugs Out of Reach for Medicare Patients KOLR, 4/6/2013 See more effects of sequestration at http://c-quest.org. By: BridgeProject21 … Continue reading →

Justin Bieber caught for doing more drugs! Well, Justin bieber is doing drugs on camera.. enjoy. By: ColeMaxfield … Continue reading →

Kingdom Hearts 2 | Ep.46 | Aladin does drugs and thinks monkeys can talk! Become a Homie 😀 and show your love by leaving a like! http://www.youtube.com/subscription_center?add_user=xxslyfoxhoundxx Official SlyFoxHound Stuck In Y... By: xXSlyFoxHoundXx … Continue reading →

THE VOICE hopeful Nadeem Leigh says his life spiralled out of control as he battled serious drugs and booze addiction from his mid teens. The reformed addict admits he was lucky to survive getting drunk and high on drugs including cannabis and cocaine EVERY DAY after he began to experiment at the age of 15. His personal life hit a new low when he was 19 after his mum Deborah died suddenly when she suffered a stroke. Nadeem, who wowed the shows judges on Saturday despite previously auditioning unsuccessfully for X Factor, said: I turned to drugs and alcohol early on in my life, I was 15. There wasnt a day that I look back and I was sober. My mum dying when I was 19 was a major factor in my addiction. It was a massive shock she was only 37 years old. I felt very lost. My relationship with my mum was a very strong one, she raised me on my own. When she died I felt completely abandoned. My dad left when I was two. I saw him on and off until I was 14 but he has never been a part of my life. The singer, … Continue reading →

TORONTO - A new report suggests spending on drugs in Canada continues to grow, but at the slowest rate in 16 years. The report says the slowed growth in prescription drug spending is due to the fact that patents expired for several blockbuster drugs, which meant people could buy cheaper generic versions of the medications. The report says Canadians spent $33 billion on drugs in 2012, or an average of $947 per person. The report, from the Canadian Institute for Health Information, says drugs continue to make up the second-largest share of health spending, after hospitals and ahead of the cost of doctors's salaries. Drugs made up 16 per cent of health spending in 2012. And prescription drugs made up 84 per cent of total drug spending in 2012. Another factor in the slowing of the growth of drug spending was a change in generic drug pricing policies. The report notes that many public drug programs reduced the amount they would pay for generic drugs. That has led to prices for many of those drugs being capped at between 25 per cent and 40 per cent of the cost of their brand name competitors. Here is the original post: Spending … Continue reading →

Seniors in the Southeast were much more likely to be prescribed more than one high-risk medications in 2009. Seniors in the Southeast were much more likely to be prescribed more than one high-risk medications in 2009. Health care types have spent years trying to make the point that seniors are being prescribed medications are unnecessary and dangerous. But the message hasn't really sunk in. More than 20 percent of people with Medicare Advantage coverage are taking at least one high-risk medication, a new study finds. People in the Southeast are especially vulnerable, the data show. In many parts of the South, more than one-third of seniors are taking drugs that they should avoid or sub out for something safer. Ten percent are taking two or more. "Geography really stands out," says Amal Trivedi, an associate professor of health services policy and practice at Brown University's Alpert Medical School. He's a co-author of the study, which was published in the April Journal of General Internal Medicine. More than 38 percent of Medicare Advantage enrollees in Albany, Ga., got at least one risky drug, compared 10 percent in Mason City, Iowa, the area with the lowest rate. The people prescribed risky drugs … Continue reading →

The world's first 'test tube baby' Britain's Louise Brown (R) listens as Professor Robert Edwards addresses the media during 25th anniversary celebrations of the revolutionary fertility treatment 'In Vitro Fertilization' ( IVF) at Bourne Hall in Cambridgeshire in this July 26, 2003 file photo. (STRINGER) Despite lingering concerns that using fertility drugs might raise a woman's chances for later developing ovarian cancer, new research suggests the drugs don't contribute any added risk. "One important message is women who need to use fertility drugs to get pregnant should not worry about using these fertility drugs," said Dr. Albert Asante, lead author of the study and a clinical fellow in the division of reproductive endocrinology at the Mayo Clinic in Rochester, Minnesota. Research on fertility drugs and cancer risk has yielded conflicting results. Some studies, especially in the 1990s, showed an increased likelihood of the cancer among women who took fertility drugs. And a Dutch report from 2011 found an increase in borderline tumors -- those with abnormal cells that might not turn into cancer. However, Dr. Bert Scoccia, a professor at the University of Illinois School of Medicine in Chicago who studies fertility medication and cancer, said numerous other studies have … Continue reading →

Treatments for rare diseases are hot properties for drugmakers, who covet the medicines for their tax breaks, through-the-roof prices, and the exclusive marketing rights granted by government regulators. Lately, though, those orphan drugsso named because they treat rare conditions for which there are no other approved treatmentsare being slammed by an unlikely culprit: the European economic slump. As more medicines win approval to treat such diseases, affecting no more than 5 in 10,000 people, Europes austerity-conscious governments are applying the same pricing scrutiny to orphan drugs that they do to widely prescribed medicines for heart disease and diabetes. Thats putting the brakes on an $86billion sector of the pharmaceutical industry thats been growing twice as fast as the market as a whole. We have seen countries which were providing good access to orphan medicinal products now questioning the continuation of reimbursement, says Yann Le Cam, chief executive officer of Eurordis, a Paris-based group that represents patients with rare diseases. In most of Europe, national health systems negotiate the pricesand then pay the billsfor orphan drugs, whose huge development costs must be spread across a minuscule number of users. This year, the Netherlands demanded cuts in the prices of rare enzyme-replacement … Continue reading →

Apr. 11, 2013 Clinical pharmacologists at Heidelberg University Hospital have achieved major progress for improving the reliability of drugs. In a pharmacological study, they showed for the first time that interactions between drugs can be detected with minute doses in the range of nanograms. However, at these low doses, the drugs are neither effective nor do they have side effects. This means that studies on interactions occurring in drug combinations can be conducted practically without posing risks or negative impacts on the participants. This is true not only for healthy volunteers, as has been observed to date, but also for patients. The study was published in the medical journal Clinical Pharmacology & Therapeutics. "Many chronically ill or elderly patients today take several different drugs. Around two percent of all hospital stays in Germany are the result of interactions between the drugs," said Professor Walter E. Haefeli, Medical Director of the Department for Clinical Pharmacology and Pharmacoepidemiology at Heidelberg University, where the new technique of "nano-dosing" has been developed and tested. "Many interactions could be avoided if we were aware of them and took them into account." Drug combinations rarely studied for interactions However, very few drug combinations have been systematically … Continue reading →

By Ben Hirschler LONDON (Reuters) - A spike in U.S. demand for flu drug Tamiflu and strong sales of mainstay cancer medicines lifted first-quarter sales at Roche Holding AG by a bigger-than-expected 5 percent. The healthy performance in its main pharmaceuticals unit - which was also bolstered by approval of two new breast cancer drugs - offset weak sales in diagnostics, and the Swiss group confirmed its forecast of rising sales and profit for 2013. The world's largest maker of cancer drugs said quarterly sales rose to 11.59 billion Swiss francs ($12.44 billion), compared with the average analyst forecast of 11.45 billion francs in a Reuters poll. Analysts at Jefferies and Sarasin said it was a good set of numbers, although diagnostics were once again disappointing. Roche stock was 0.3 percent higher by 02:10 ET. Sales in the smaller diagnostics business were up just 1 percent in the quarter with diabetes care down 5 percent, due to stiff competition and pricing pressure. Demand for Tamiflu - a smaller seller than Roche's cancer blockbusters - accounted for half the beat in the pharma division, with sales surging 84 percent in the quarter following a severe flu season in the United States. … Continue reading →